Granted Patent
B2
US 12,466,795 · App. 18/308,037 · Granted Nov 11, 2025
Isoindoline compositions and methods for treating neurodegenerative disease
Inventors:
Gilbert M. Rishton (Los Angeles, CA); Susan M. Catalano (Pittsburgh, PA); Gary C. Look (Santa Clara, CA)
Assignee:
Cognition Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
Claims (7)
1 . A pharmaceutical composition comprising 10 to 2000 mg of a compound of the Formula:
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
2 . The pharmaceutical composition of claim 1 wherein the compound is
3 . The pharmaceutical composition of claim 1 wherein the composition comprises 10 to 300 mg of the compound.
4 . The pharmaceutical composition of claim 1 wherein the composition comprises 20 to 150 mg of the compound.
5 . The pharmaceutical composition of claim 1 wherein the composition is formulated for oral delivery.
6 . The pharmaceutical composition of claim 1 wherein the composition is in a capsule or tablet.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 27, 2023
From: RISHTON, GILBERT M.; CATALANO, SUSAN M.; LOOK, GARY C.
To: COGNITION THERAPEUTICS, INC.
Reel/Frame 063462/0337 →
Continuity (6)
Continuation
15115187
Provisional Application
61934528
· Jan 31, 2014
References Cited (264)
US 4321386A
· Lawson
· 1982
[cited by applicant]
US 4582849A
· Marzolph et al.
· 1986
[cited by applicant]
US 4697024A
· Donaldson et al.
· 1987
[cited by applicant]
US 4958029A
· Nakagawa et al.
· 1990
[cited by applicant]
US 6011068A
· Nemeth et al.
· 2000
[cited by applicant]
US 6057371A
· Glennon
· 2000
[cited by applicant]
US 6211244B1
· Van et al.
· 2001
[cited by applicant]
US 6235731B1
· Shibouta et al.
· 2001
[cited by applicant]
US 6518315B1
· Roufogalis et al.
· 2003
[cited by applicant]
US 6991814B2
· Ray et al.
· 2006
[cited by applicant]
US 7723377B2
· Rishton et al.
· 2010
[cited by applicant]
US 8304547B2
· Sugasawa et al.
· 2012
[cited by applicant]
US 8765816B2
· Rishton et al.
· 2014
[cited by applicant]
US 9192585B2
· Rishton et al.
· 2015
[cited by applicant]
US 9365491B2
· Rishton et al.
· 2016
[cited by applicant]
US 9499462B2
· Rishton et al.
· 2016
[cited by applicant]
US 9796672B2
· Rishton
· 2017
[cited by examiner]
US 9815770B2
· Rishton et al.
· 2017
[cited by applicant]
US 20060153772A1
· Jacobsen
· 2006
[cited by applicant]
US 20070021413A1
· Herold et al.
· 2007
[cited by applicant]
US 20080131233A1
· Yao
· 2008
[cited by applicant]
US 20080153917A1
· Ellis et al.
· 2008
[cited by applicant]
US 20080171757A1
· Eaton et al.
· 2008
[cited by applicant]
US 20080193573A1
· Gow et al.
· 2008
[cited by applicant]
US 20080312333A1
· Mae et al.
· 2008
[cited by applicant]
US 20090017038A1
· Colabufo et al.
· 2009
[cited by applicant]
US 20090035295A1
· Hillen et al.
· 2009
[cited by applicant]
US 20100028333A1
· Getty et al.
· 2010
[cited by applicant]
US 20100029654A1
· Pasinetti
· 2010
[cited by applicant]
US 20100093001A1
· Rousseau et al.
· 2010
[cited by applicant]
US 20110015209A1
· Shamloo et al.
· 2011
[cited by applicant]
US 20110082154A1
· Oksenberg et al.
· 2011
[cited by applicant]
US 20110092554A1
· Chesworth et al.
· 2011
[cited by applicant]
US 20130071330A1
· Catalano
· 2013
[cited by applicant]
US 20140378460A1
· Catalano et al.
· 2014
[cited by applicant]
US 20140378473A1
· Catalano et al.
· 2014
[cited by applicant]
US 20150160228A1
· Catalano
· 2015
[cited by applicant]
US 20170197977A9
· Catalano et al.
· 2017
[cited by applicant]
US 20230098944A1
· Catalano
· 2023
[cited by examiner]
US 20240009168A1
· Caggiano et al.
· 2024
[cited by applicant]
AU 2008314922A1
· 2009
[cited by applicant]
CA 1018188A
· 1977
[cited by applicant]
CA 1275934C
· 1990
[cited by applicant]
CA 2073841A1
· 1993
[cited by applicant]
CN 101121670A
· 2008
[cited by applicant]
CN 110283082A
· 2019
[cited by applicant]
DE 4000610A1
· 1991
[cited by applicant]
DE 10320560A1
· 2004
[cited by applicant]
EP 0002222A1
· 1979
[cited by applicant]
EP 0443606A2
· 1991
[cited by applicant]
EP 0613007A2
· 1994
[cited by applicant]
EP 0881220A1
· 1998
[cited by applicant]
EP 1088550A1
· 2001
[cited by applicant]
JP H01180822A
· 1989
[cited by applicant]
JP H01305085A
· 1989
[cited by applicant]
JP H02215789A
· 1990
[cited by applicant]
JP H045266A
· 1992
[cited by applicant]
JP H06321781A
· 1994
[cited by applicant]
JP H0915744A
· 1997
[cited by applicant]
JP 2003113117A
· 2003
[cited by applicant]
JP 2004002517A
· 2004
[cited by applicant]
WO 8202551A1
· 1982
[cited by applicant]
WO 9109594A1
· 1991
[cited by applicant]
WO 9511221A1
· 1995
[cited by applicant]
WO 9612697A2
· 1996
[cited by applicant]
WO 9925363A1
· 1999
[cited by applicant]
WO 9929673A1
· 1999
[cited by applicant]
WO 0130335A2
· 2001
[cited by applicant]
WO 0191558A1
· 2001
[cited by applicant]
WO 03016274A2
· 2003
[cited by applicant]
WO 03051380A2
· 2003
[cited by applicant]
WO 2005087212A1
· 2005
[cited by applicant]
WO 2006020879A1
· 2006
[cited by applicant]
WO 2006138349A1
· 2006
[cited by applicant]
WO 2007077543A2
· 2007
[cited by applicant]
WO 2009059214A1
· 2009
[cited by applicant]
WO 2010062260A1
· 2010
[cited by applicant]
WO 2010088450A2
· 2010
[cited by applicant]
WO WO2013029057A2
· 2013
[cited by examiner]
WO 2015020523A1
· 2015
[cited by applicant]
Aboul-Enein et al. “Synthesis of Certain 1,7,7-Trimethyibicyclo [2.2.1] Heptane Derivatives With Anticonvulsant, Hypoglycemic, and Anti-inflammatory Potential” 2006, J.Iranian Chemical Society, 2 Pages, CASREACT 147:100…
[cited by applicant]
Adams et al. “The Leaf Essential Oils and Taxonomy of
[cited by applicant]
Albright “Diverse Approaches to Alzheimer's Therapies Continue to Show Progress at ICAD” Jul. 26-31, 2008, International Conference on Alzheimer's Disease, 5 Pages.
[cited by applicant]
Arai et al. “Chemically Conditioned Extracts of Ginger Oil: Leadlike Alkaloidal Compounds Derived From Natural Extracts via Reductive Amination” Wednesday Jan. 25, 2006, General Biochemistry Biotechnology and Pharmaceut…
[cited by applicant]
Balaji et al. “Toxicity Prediction of Compounds from Turmeric” 2010, Food and Chemical Toxicology 48:2951-2959.
[cited by applicant]
Banerjee et al. “Chemical Modification of Turmeric Oil to More Value Added Products” 1981, Indian Perfumer 25:25-30.
[cited by applicant]
Barghorn et al. “Globular Amyloid Beta-Peptide 1-42 Oligomer—A Homogenous and Stable Neuropathological Protein in Alzheimer's Disease” Nov. 2005, J. Neurochemistry 953:834-847.
[cited by applicant]
Batra et al. “Hydrogenolysis of 3-methyl-4-phenyimethyl-52H-isoxazoione Derivatives: A Reinvestigation” Jan. 1992, Indian J. Chemistry 31B:60-62.
[cited by applicant]
Beckurts et al. “Archiv der Pharmazie and Berichte der Deutschen Pharmazeutischen Gessellschaft” 1927, 265:15-26.
[cited by applicant]
Begum et al. “Curcumin Structure-Function Bioavailability and Efficacy in Models of Neuroinflammation and Alzheimers Disease” Feb. 4, 2008, J. Pharmacology and Experimental Therapeutics 3261:196-208.
[cited by applicant]
Belikov “Pharmaceutical Chemistry” 1993, Moscow, Vyshaya Shkola Publishing House, 43-46(14 Pages), (English Machine Translation provided).
[cited by applicant]
Blossom et al. “Beyond Mild Cognitive Impairment: Vascular Cognitive Impairment, No. Dementia (VCIND)” 2009, Alzheimer's Research Therapy 1(1):16 Pages.
[cited by applicant]
Bornholdt et al. “Ring Opening of Pymisyl-Protected Aziridines with Organocuprates” 2010, Chemistry A European Journal 16:12474-12480.
[cited by applicant]
Brody et al. “Amyloid-Beta Dynamics Correlate with Neurological Status in the Injured Human Brain” Aug. 29, 2008, Science 321(5893):1221-1224.
[cited by applicant]
Bu “Apolipoprotein E and Its Receptors in Alzheimer's Disease: Pathways Pathogenesis and Therapy” May 2009, Nature Reviews Neuroscience 105:333-344.
[cited by applicant]
Calabrese et al. “Rapid Concurrent Alternations in Pre-and Postsynaptic Structure Induced by Naturally-Secreted Amyloid-Beta Protein” Feb. 2, 2007, Molecular and Cellular Neuroscience, 1-11.
[cited by applicant]
Campbell “Beta-Amyloid: Friend or Foe” 2001, Medical Hypotheses 563:388-391.
[cited by applicant]
Casagrande et al. “Synthesis of Some Isoindolines and 1234-Tetrahydroisoquinolines and their Evaluation as Alpha-Adrenergic and Adrenergic Neuron Blocking Agents” 1972, IL Farmaco Edizione Scientifica 27:445-470.
[cited by applicant]
Catalano et al. “The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimer's Disease” 2006, Current Topics in Medicinal Chemistry 66:597-608.
[cited by applicant]
Chang et al. “AMPA Receptor Downscaling at the onset of Alzheimer's Disease Pathology in Double Knockin Mice” Feb. 28, 2006, Proceedings of the National Academy of Sciences of the United States of America 103(09):3410-3…
[cited by applicant]
Chang et al. “Supercritical Carbon Dioxide Extraction of Turmeric Oil from Curcuma Longa Linn and Purification of Turmerones” 2006, Separation and Purification Technology 47:119-125.
[cited by applicant]
European Search Report and Written Opinion for European Application No. 12824979.4 mailed Apr. 15, 2015 (7 pages).
[cited by applicant]
European Search Report and Written Opinion for European Application No. 12825341.6 mailed Sep. 21, 2015 (19 pages).
[cited by applicant]
European Search Report and Written Opinion for European Application No. 15743281.6 mailed Jun. 19, 2017 (8 pages).
[cited by applicant]
European Search Report and Written Opinion for European Application No. 18802363 mailed Mar. 5, 2021 (12 pages).
[cited by applicant]
European Search Report and Written Opinion for European Application No. 18873712.6 mailed Jul. 22, 2021 (6 pages).
[cited by applicant]
European Search Report and Written Opinion for European Application No. 19154222.4 mailed Mar. 19, 2019 (5 pages).
[cited by applicant]
European Search Report and Written Opinion for European Application No. 22155541.0 mailed Apr. 4, 2022 (5 pages).
[cited by applicant]
Fenili et al. “Properties of Scyllo-inositol as a Therapeutic Treatment of AD-like Pathology” Jun. 2007, Journal of Molecular Medicine 856:603-611.
[cited by applicant]
Flood et al. “FAD Mutant PS-1 gene-targeted Mice: Increased Abeta42 and Abeta Deposition Without APP Overproduction” May-Jun. 2002, Neurobiology of Aging 233:335-348.
[cited by applicant]
Fujiwara et al. “Acetylcholinesterase Inhibitory Activity of Volatile Oil from Peltophorum Dasyrachis Kurz ex Bakar (Yellow Batai) and Bisabolane-Type Sesquiterpenoids” Jan. 2010, Journal of Agricultural and Food Chemis…
[cited by applicant]
Fukumoto et al. “Beta-Secretase Activity Increases with Aging in Human Monkey and Mouse Brain” Feb. 2004, The American Journal of Pathology, 164(2):719-725.
[cited by applicant]
Gennaro “Remington's Pharmaceutical Sciences 17th Ed.” 1985, Mack Publishing Company, Easton, Pennsylvania 19 Pages.
[cited by applicant]
Georganopoulou et al. “Nanoparticle-Based Detection in Cerebral Spinal Fluid of a Soluble Pathogenic Biomarker For Alzheimer's Disease” Feb. 15, 2005, Proceedings of the National Academy of Sciences 102(7):2273-2276.
[cited by applicant]
Golde “Alzheimer Disease Therapy: Can the Amyloid Cascade be Halted?” Jan. 2003, J. Clinical Investigation 111(1):11-18.
[cited by applicant]
Gopalan et al. “Supercritical Carbon Dioxide Extraction of Turmeric (Curcuma Longa)” 2000, J. Agricultural and Food Chemistry 48:2189-2192.
[cited by applicant]
Gortz et al. “Neuronal Network Properties of Human Teratocarcinoma Cell Line-Derived Neurons” Aug. 20, 2004, Brain Research 1018:18-25.
[cited by applicant]
Greene et al. “Protective Groups in Organic Synthesis 3rd Ed.” 1999, John Wiley & Sons Incorporated, New York 4 Pages.
[cited by applicant]
Griffith et al. “Elevated Brain Scyllo-Inositol Concentrations in Patients With Alzheimer's Disease” Dec. 2007, NMR in Biomedicine 20:709-716.
[cited by applicant]
Grzanna et al. “Ginger—An Herbal Medicinal Product with Broad Anti-Inflammatory Actions” 2005, J. Medicinal Food 8(2):125-132.
[cited by applicant]
Hampel et al. “Core Candidate Neurochemical And Imaging Biomarkers of Alzheimer's Disease” Jan. 2008, Alzheimer's & Dementia 4(1):38-48.
[cited by applicant]
Hansson et al. “Reduced Levels of Amyloid-Beta-Binding Proteins in Cerebrospinal Fluid from Alzheimer's Disease Patients” 2009, J. Alzheimer's Disease 16(2):389-397.
[cited by applicant]
Ho et al. “Heterogeneity in Red Wine Polyphenolic Contents Differentially Influences Alzheimer's Disease-type Neuropathology and Cognitive Deterioration” 2009, J . Alzheimer's Disease 16(1):59-72.
[cited by applicant]
Hong., et al., “Candidate anti-A(Beta) Fluorine Compounds Selected From Analogs of Amyloid Imaging Agents” Oct. 2010, J. Neurobiology of Aging 31(10):1690-1699.
[cited by applicant]
Hong et al. “Combining the Rapid MTT Formazan Exocytosis Assay and the MC65 Protection Assay Led to the Discovery of Carbazole Analogs as Small Molecule Inhibitors of A(Beta) Oligomer-Induced Cytotoxicity” Jan. 26, 2007…
[cited by applicant]
Hong et al. “Inhibition of Alzheimer's Amyloid Toxicity with a Trycyclic Pyrone Molecule In Vitro and In Vivo” Feb. 2009, J. Neurochemistry 108(4):1097-1108.
[cited by applicant]
Hsieh et al. “AMPA-R Removal Underlies A(Beta)-Induced Synaptic Depression and Dendritic Spine Loss” Dec. 7, 2006, Neuron 52(5):831-843.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/018023 dated Jun. 25, 2021, 13 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2010/030130, mailed Jun. 10, 2010, 10 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2012/023483, mailed May 31, 2012, 11 Pages.
[cited by applicant]
Townsend et al. “Orally Available Compound Prevents Deficits in Memory Caused by the Alzheimer Amyloid-ß Oligomers” Dec. 2006, Annals of Neurology 60(06):668-676.
[cited by applicant]
Turner et al. “Roles of Amyloid Precursor Protein And its Fragments in Regulating Neural Activity, Plasticity And Memory” May 2003, Progress in Neurobiology 70(1):1-32.
[cited by applicant]
Uehara et al. “New Bisabolane Sesquiterpenoids From the Rhizomes of Curcuma Xanthorrhiza (Zingiberaceae)” Jan. 1989, Chemical and Pharmaceutical Bulletin 37(1)237-240.
[cited by applicant]
Verdile et al. “The Role of Beta Amyloid in Alzheimer's Disease: Still A Cause of Everything or the Only One Who Got Caught?” Oct. 2004, Pharmacological Research 50(4):397-409.
[cited by applicant]
Walsh et al. “Certain Inhibitors of Synthetic Amyloid Beta-peptide (A-Beta) Fibrillogenesis Block Oligomerization of Natural A-Beta and Thereby Rescue Long-term Potentiation” Mar. 9, 2005, The J. Neuroscience, 25(10):24…
[cited by applicant]
Walsh et al. “Naturally Secreted Oligomers of Amyloid Beta Protein Potently Inhibit Hippocampal Long-term Potentiation In Vivo” Apr. 4, 2002, Nature 416:535-539, DOI:10.1038/416535a, XP002348771.
[cited by applicant]
Wang et al. “A Versatile Catalyst for Reductive Amination by Transfer Hydogenation” 2010, Angewandte Chemie 49:7548-7552.
[cited by applicant]
Wang et al. “Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid Beta-Peptide in Hippocampal Slices is Mediated Via Activation of the Kinases c-Jun N-Terminal Kinase Cyclin-Dependent Kinase 5 and…
[cited by applicant]
Wang et al. “Grape-Derived Polyphenolics Prevent A-Beta Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer's Disease” Jun. 18, 2008, The J. Neuroscience 28(25):6388-6392.
[cited by applicant]
Wang et al. “Moderate Consumption of Cabernet Sauvignon Attenuates A-Beta Neuropathology in a Mouse Model of Alzheimer's Disease” Nov. 2006, The FASEB Journal 20(13):2313-2320.
[cited by applicant]
Wang et al. “Soluble Oligomers of Beta Amyloid (1-42) Inhibit Long-term Potentiation But not Long-term Depression in Rat Dentate Gyrus” Jan. 11, 2002, Brain Research 924:133-140.
[cited by applicant]
Weiyan et al. “Research Advances on Chemistry and Pharmacology of Zingiber Officinale” 2008, Chinese J. Ethnomedicine and Ethnopharmacy 21 Pages.
[cited by applicant]
West et al. “Hippocampal Neurons in Pre-Clinical Alzheimer's Disease” Oct. 2004, Neurobiology of Aging 25(9)1205-1212.
[cited by applicant]
Whitlock et al. “Learning Induces Long-Term Potentiation in the Hippocampus” Aug. 25, 2006, Science 313(5790):1093-1097.
[cited by applicant]
Wolozin “Cholesterol and the Biology of Alzheimer's Disease” Jan. 8, 2004, Neuron (41):7-10.
[cited by applicant]
Yang et al. “New ELISAs with High Specificity for Soluble Oligomers of Amyloid Beta-Protein Detect Natural A-Beta Oligomers in Human Brain But not CSF” Mar. 2013, Alzheimer's and Dementia 9(2):99-112.
[cited by applicant]
Yao et al. “The Ginkgo Biloba Extract EGb 761 Rescues the PC12 Neuronal Cells From Beta-Amyloid-Induced Cell Death by Inhibiting The Formation of Beta-Amyloid-Derived Diffusible Neurotoxic Ligands” Jan. 19, 2001, Brain …
[cited by applicant]
Yu et al. “Per-6-Substituted Beta-Cyclodextrin Libraries Inhibit Formation of Beta-Amyloid-Peptide A(Beta)-Derived, Soluble Oligomers” Aug.-Oct. 2002, J. Molecular Neuroscience 19(1-2):51-55.
[cited by applicant]
Zhang et al. “A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays,” Journal Biomolecular Screening, 1999, vol. 4, No. 2, pp. 67-73.
[cited by applicant]
Zhang et al. “Chiral Benzyl Centers Through Asymmetric Catalysis. A Three-Step Synthesis of (R)-(-)-Alpha-Curcumene Via Asymmetric Hydrovinylation” Aug. 3, 2004, Organic Letters, American Chemical Society 6(18):3159-316…
[cited by applicant]
Zhao et al. “Amyloid Beta Oligomers Induce Impairment Of Neuronal Insulin Receptors” 2008, The FASEB J. (22):246-260.
[cited by applicant]
Zhao et al. “Identification of Antihypertensive Drugs which Inhibit Amyloid-Beta Protein Oligomerization” J. Alzheimer's Disease, 2009, 16(1):49-57.
[cited by applicant]
Zlokovic “New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease” Jul. 2008, Neurotherapeutics 5(3), pp. 409-414, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2012/052572, mailed Feb. 25, 2013, 12 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2007/079850 dated Jun. 3, 2008, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2010/044136 dated Sep. 24, 2010, 12 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2011/026530 dated Jun. 30, 2011, 15 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2012/052578 dated Jan. 18, 2013, 12 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2015/013754 dated Apr. 30, 2015, 17 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2018/032726 dated Sep. 21, 2018, 10 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2021/062850 dated Feb. 28, 2022, 10 Pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/020687 dated Jul. 26, 2022, 11 Pages.
[cited by applicant]
Ishikawa et al. “The Role of Sigma-1 Receptors in the Pathophysiology of Neuropsychiatric Diseases” 2010, J. Receptor, Ligand and Channel Research, 3:25-36 Retrieved from the Internet: https://www.researchgate.net/publi…
[cited by applicant]
Izzo et al. “Preclinical and Clinical Biomarker Studies of CT1812: A Novel Approach to Alzheimer's disease Modification” 2021, Alzheimer's Dementia, 17:1365-1382.
[cited by applicant]
Jacobsen et al. “GSI-953 is a Potent APP-Selective Gamma-Secretase Inhibitor for the Treatment of Alzheimer's Disease” 2008, Oral 03-06: Therapeutics and Therapeutic Strategies: Novel Targets, 1 Page.
[cited by applicant]
Japanese Office Action mailed Oct. 9, 2018 for Japanese Application No. 2016549224 with English Translation, 10 Pages.
[cited by applicant]
Japanese Search Report for Japanese Application No. 2016-549224, dated Sep. 7, 2018, 36 Pages.
[cited by applicant]
Jiang et al. “Metal-Organic Conjugated Microporous Polymers” 2011, Angewandte Chemie International Edition, 50:1072-1075.
[cited by applicant]
Jin et al. “Novel Tricyclic Pyrone Compounds Prevent Intracellular APP C99-induced Cell Death” Aug.-Oct. 2002, J. Molecular Neuroscience, 19(1-2):57-61.
[cited by applicant]
Johansson et al. “Physiochemical Characterization of the Alzheimer's Disease-related Peptides A(Beta)1-42Arctic and A(Beta)1-42wt” Jun. 2006, The FEBS Journal, 273(12):2618-2630.
[cited by applicant]
Kaech et al. “Culturing Hippocampal Neurons” 2006, Nature Protocols 1(5):2406-2415, DOI:10.1038/nprot.2006.356, XP055169186.
[cited by applicant]
Kamal et al. “Total Synthesis of (R)-and (S)-Turmerone and (7S,9R)-Bisacumol by an Efficient Chemoenzymatic Approach” 2009, Tetrahedron: Asymmetry 20:1267-1271.
[cited by applicant]
Kamenetz et al. “APP Processing and Synaptic Function” Mar. 27, 2003, Neuron 37(6):925-937, DOI:10.1016/S0896-6273(03)00124-7, XP055066435.
[cited by applicant]
Kholodov et al. “Clinical Pharmacokinetics.” Meditsina, Moscow (1985): 83-89. English Machine Translation provided.
[cited by applicant]
Kimura et al. “Chemical Structural Requirement in Gingerol Derivatives for Potentiation of Prostaglandin F2(Alpha)-Induced Contraction in Isolated Mesenteric Veins of Mice” 1989, J. Pharmacobio-Dynamics 12:220-227.
[cited by applicant]
Klyubin et al. “Amyloid (Beta) Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization” Apr. 16, 2008, The J. Neuroscience 28(16):4231-4237.
[cited by applicant]
Koffie et al. “Oligomeric Amyloid Beta Associates with Postsynaptic Densities and Correlates with Excitatory Synapse Loss Near Senile Plaques” Mar. 10, 2009, Proceedings of the National Academy of Sciences of the United…
[cited by applicant]
Kornhuber et al. “Cerebrospinal Fluid and Serum Concentrations of The N-methyl-D-aspartate (NMDA) Receptor Antagonist Memantine in Man” Aug. 4, 1995, Neuroscience Letters 195(2):137-139.
[cited by applicant]
Kotilinek et al. “Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease” Aug. 1, 2002, The J. Neuroscience, 22(15):6331-6335.
[cited by applicant]
Krafft et al. “ADDLs and the Signaling Web that Leads to Alzheimer's Disease” 2010, Neuropharmacology 59:230-242.
[cited by applicant]
Lacor et al. “A(Beta) Oligomer-Induced Aberrations in Synapse Composition Shape and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease” Jan. 24, 2007, The J. Neuroscience, 27(4):796-807.
[cited by applicant]
Lacor et al. “Synaptic Targeting by Alzheimer's-Related Amyloid Beta Oligomers” 2004, The J. Neuroscience 24(45):10191-10200.
[cited by applicant]
Lambert et al. “Diffusible Nonfibrillar Ligands Derived from A(Beta)1-42 are Potent Central Nervous System Neurotoxins” May 26, 1998, Proceedings of the National Academy of Sciences of the United States of America 95(11…
[cited by applicant]
Lambert et al. “Monoclonal Antibodies That Target Pathological Assemblies of A(Beta)” Jan. 2007, J. Neurochemistry 100:23-35.
[cited by applicant]
Lannfelt et al. “Safety, Efficacy, and Biomarker Findings of PBT2 in Targeting A(Beta) as s Modifying Therapy for Alzheimer's Disease: A Phase IIa, Double-blind, Randomized, Placebo-controlled Trial” Sep. 2008, Lancet N…
[cited by applicant]
Lauren J., et al. “Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-szlig; Oligomers” Feb. 26, 2009, Nature 457(7233):1128-1132, DOI:doi:10.1038/nature07761, XP009120514.
[cited by applicant]
Leal et al. “Functional Properties of Spice Extracts Obtained Via Supercritical Fluid Extraction” 2003, J. Agricultural and Food Chemistry 51(9):2520-2525.
[cited by applicant]
Lecanu et al. “Identification of Naturally Occurring Spirostenols Preventing Beta-Amyloid-Induced Neurotoxicity” Jan. 2004, Steroids 69:1-16.
[cited by applicant]
Lesne et al. “A Specific Amyloid-Beta Protein Assembly in the Brain Impairs Memory” Mar. 16, 2006, Nature, 440(7082):352-357, DOI:10.1038/nature04533, XP002408133.
[cited by applicant]
Lesuisse et al. “Long-term Culture of Mouse Cortical Neurons as a Model for Neuronal Development, Aging, and Death” 2002, J. Neurobiology, 51:9-23.
[cited by applicant]
Levine “Alzheimer's Beta-Peptide Oligomer Formation at Physiologic Concentrations” Dec. 1, 2004, Analytical Biochemistry, 335(1):81-90.
[cited by applicant]
Levine “Biotin-Avidin Interaction-Based Screening Assay For Alzheimer's Beta-peptide Oligomer Inhibitors” 2006, Analytical Biochemistry, 356:265-272.
[cited by applicant]
Li et al. “Soluble Oligomers of Amyloid Beta-Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake” Jun. 25, 2009, Neuron, 62(6):788-801.
[cited by applicant]
Li et al. “Total Asymmetric Synthesis of (7S,9R)-(+)-Bisacumol” 2003, Tetrahedron: Asymmetry, 14:75-78.
[cited by applicant]
Liu et al. “Amyloid Beta Peptide Alters Intracellular Vesicle Trafficking and Cholesterol Homeostasis” Oct. 1998, Proceedings of the National Academy of Sciences of the United States of America, 95:13266-13271.
[cited by applicant]
Liu et al. “Cytotoxic Amyloid Peptides Inhibit Cellular 3-(4,5-Dimethyithiazol-2yl)-2,5-Diphenyitetrazolium Bromide (MTT) Reduction by Enhancing MTT Formazan Exocytosis” Dec. 1997, J. Neurochemistry, 69(6):2285-2293.
[cited by applicant]
Liu et al. “Treating Alzheimer's Disease by Inactivating Bioactive Amyloid Beta Peptide” Apr. 2006, Current Alzheimer Research 3(2):129-135.
[cited by applicant]
Liu Y et al. “Detecting Bioactive Amyloid Beta Peptide Species in Alzheimer's Disease” Nov. 2004, J. Neurochemistry, 91(3):648-656.
[cited by applicant]
Lleo et al. “Clinical, Pathological and Biochemical Spectrum of Alzheimer Disease Associated with PS-1 Mutations” Mar.-Apr. 2004, The American Journal of Geriatric Psychiatry, 12(2):146-156.
[cited by applicant]
Look et al. “Discovery of ADDL-Targeting Small Molecule Drugs for Alzheimer's Disease” Dec. 2007, Current Alzheimer Research 4:562-567.
[cited by applicant]
Maezawa et al. “A Novel Tricyclic Pyrone Compound Ameliorates Cell Death Associated with Intracellular Amyloid-Beta Oligomeric Complexes” Jul. 2006, J. Neurochemistry 98(1):57-67.
[cited by applicant]
Maier et al. “Synthesis and SAR Studies of 3-Substituted 1′-Benzylspiro[[2]Benzoxepine-1,4′-Piperidines]” Feb. 2003, European J. of Organic Chemistry 4:714-720.
[cited by applicant]
Majno et al. “Apoptosis, Oncosis, and Necrosis: An Overview of Cell Death” Jan. 1995, The American J. Pathology 146(1):13 Pages.
[cited by applicant]
Mann et al. “Amyloid Angiopathy and Variability in Amyloid Beta Deposition is Determined by Mutation Position in Presenilin-1-Linked Alzheimer's Disease” Jun. 2001, The American J. of Pathology 158(6):2165-2175.
[cited by applicant]
Masaki et al. “A Facile Regio-and Sterio-Specific Allylic Oxidation of Gem-Dimethyl Olefins Via Addition of Benzenesulphenyl Chloride, Synthesis of Allylic Oxygenated Terpenes” Jul. 4, 1984, J. of the Chemical Society P…
[cited by applicant]
Masuda et al. “Antioxidant Properties of Gingerol Related Compounds from Ginger” 2004, Biofactors 21(1-4):293-296.
[cited by applicant]
Matsubara et al. “Soluble A(Beta) homeostasis in AD and DS: Impairment of Anti-Amyloidogenic Protection by Lipoproteins” Aug. 2004, Neurobiology of Aging 25(7):833-841.
[cited by applicant]
Matsuda et al. “Hepatoprotective Constituents from Zedoariae Rhizoma: Absolute Stereostructures of Three New Carabrane-Type Sesquiterpenes, Curcumenolactones A, B, and C” 2001, Bioorganic Medicinal Chemistry, 9:909-916.
[cited by applicant]
Matsuda et al. “Medicinal Foodstuffs. XXVIII. Inhibitors of Nitric Oxide Production and New Sesquiterpenes, Zedoarofuran, 4-Epicurcumenol, Neocurcumenol, Gajutsulactones A and B, and Zedoarolides A and B, from Zedoariae…
[cited by applicant]
Maurice et al. “The Pharmacology of Sigma-1 Receptors” Nov. 2009, Pharmacology Therapeutics 124(2):195-206.
[cited by applicant]
Mayer et al. “Discovery of Begacestat a Notch-1-Sparing ?-Secretase Inhibitor for the Treatment of Alzheimer's Disease” Oct. 3, 2008, J. of Medicinal Chemistry 51:7348-7351.
[cited by applicant]
Miklossy et al. “Two Novel Presenilin-1 Mutations (Y256S And Q222H) are Associated with Early-Onset Alzheimer's Disease” Sep. 2003, Neurobiology of Aging 24(5):655-662.
[cited by applicant]
Mori et al. “Synthesis of a Mixture of +-Dehydrojuvabione and its Stereoisomer” 1967, Tetrahedron Letters 48:4853-4856.
[cited by applicant]
Morris “D.O. Hebb: The Organization of Behavior” May 19, 1999, Wiley: New York, 1949, Brain Research Bulletin 50(5/6):437-438.
[cited by applicant]
Morris “Episodic-like Memory In Animals: Psychological Criteria, Neural Mechanisms and the Value of Episodic-like Tasks to Investigate Animal Models of Neurodegenerative Disease” Sep. 29, 2001, Philosophical Transaction…
[cited by applicant]
Mucke L., et al., “High-Level Neuronal Expression of Aβ1-42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity Without Plaque Formation,” Journal of Neuroscience, Jun. 1, 2000, vol. 20(11), pp…
[cited by applicant]
Mukaiyama et al. “N-Alkylation of Phthalimide, Carboxamide, and Sulfonamides By Oxdation-Reduction Condensation Using Di-tert-butyl-1,4-benzoquinone and Alkyl Diphenylphosphinite” Apr. 25, 2004, Chemistry Letters, Japan…
[cited by applicant]
Mustafa et al. “Drug Development Report (9): Pharmacology of Ginger, Zingiber Officinale” 1993, J. Drug Development 6(1):25-39.
[cited by applicant]
Negron et al. “Study of the Asymmetric Induction of the 1,3-Dipolar Cycloaddition of Chiral Azomethine Ylides with Unactivated Double Bonds” 1992, CASREACT 117(426230):2 Pages.
[cited by applicant]
Nielsen et al. “Binding and Uptake of A(Beta)1-42 by Primary Human Astrocytes In Vitro” 2009, GLIA 57:978-988.
[cited by applicant]
Nikolaev et al. “N-APP Binds DR6 to Cause Axon Pruning and Neuron Death Via Distinct Caspases” Feb. 19, 2009, Nature 457:(232):981-989.
[cited by applicant]
Nomura et al. “Mechanism of Impairment of Long-term Potentiation by Amyloid Beta is Independent of NMDA Receptors or Voltage-Dependent Calcium Channels in Hippocampal CA1 Pyramidal Neurons” Dec. 31, 2005, Neuroscience L…
[cited by applicant]
Ono et al. “Effects of Grape Seed-Derived Polyphenols on Amyloid Beta-Protein Self-Assembly and Cytotoxicity” Nov. 12, 2008, J. Biological Chemistry 283(47):32176-32187.
[cited by applicant]
Plant et al. “The Production of Amyloid Beta Peptide is a Critical Requirement for the Viability of Central Neurons” Jul. 2003, The J. Neuroscience, 23(13):5531-5535.
[cited by applicant]
Poling et al. “Oligomers of the Amyloid-Beta Protein Disrupt Working Memory: Confirmation with Two Behavioral Procedures” Nov. 21, 2008, Behavioural Brain Research, 193(2):230-234.
[cited by applicant]
Price et al. “Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease” Sep. 2001, Archives of Neurology, 58(9):1395-1402.
[cited by applicant]
Priller et al. “Mutant Presenilin 1 Alters Synaptic Transmission in Cultured Hippocampal Neurons” Jan. 12, 2007, J. Biological Chemistry, 282(2):1119-1127.
[cited by applicant]
PubChem “SID 285282520” Jan. 15, 2016, Aurora Fine Chemicals LLC 5 Pages.
[cited by applicant]
Puzzo et al. “Amyloid-Beta Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway During Hippocampal Synaptic Plasticity” Jul. 20, 2005, The J. Neuroscience, 25(29):6887-689…
[cited by applicant]
Puzzo et al. “Picomolar Amyloid-Beta Positively Modulates Synaptic Plasticity and Memory in Hippocampus” Dec. 31, 2008, The J. Neuroscience, 28(53):14537-14545.
[cited by applicant]
Rana et al. “Syntheses of Tricyclic Pyrones and Pyridinones and Protection of A(Beta)-Peptide Induced MC65 Neuronal Cell Death” Feb. 1, 2009, Bioorganic Medicinal Chemistry Letters, 19(3):670-674.
[cited by applicant]
Rishton et al. “Computational Approaches to the Prediction of Blood-Brain Barrier Permeability: A Comparative Analysis of Central Nervous System Drugs Versus Secretase Inhibitors For Alzheimer's Disease” May 2006, Curre…
[cited by applicant]
Rishton et al. “Nonleadlikeness and Leadlikeness in Biochemical Screening” Jan. 15, 2003, Drug Discovery Today 8(2):86-96.
[cited by applicant]
Rishton “Reactive Compounds and In Vitro False Positives in HTS” Sep. 9, 1997, DDT 2(9):382-384.
[cited by applicant]
Ronicke et al. “A(Beta) Mediated Diminution of MTT Reduction-An Artifact of Single Cell Culture?” Sep. 18, 2008, PLOS One, 3(9), 9 Pages, e3236.
[cited by applicant]
Rowan et al. “Mechanisms of the Inhibitory Effects of Amyloid Beta-Protein on Synaptic Plasticity” November- Dec. 2004, Experimental Gerontology 39(11-12):1661-1667.
[cited by applicant]
Sampson et al. “Metal Protein Attenuating Compounds for the Treatment of Alzheimer's Disease (Review)” 2009, The Cochrane Collaboration, Issue 1, 15 Pages.
[cited by applicant]
Scheff et al. “Hippocampal Synaptic Loss in Early Alzheimer's Disease and Mild Cognitive Impairment” Oct. 2006, Neurobiology of Aging 27(10):1372-1384.
[cited by applicant]
Scheff et al. “Synaptic Alternations In Ca1 Mild Alzheimer Disease And Mild Cognitive Impairment” May 1, 2007, Neurology, 68:1501-1508.
[cited by applicant]
Sejnowski et al. “The Book of Hebb: Minireview” Dec. 1999, Neuron 24:773-776.
[cited by applicant]
Sergeeva “A Short Course of Molecular Pharmacology” 1975, Moscow, 6 Pages.
[cited by applicant]
Shankar et al. “Amyloid-Beta Protein Dimers Isolated Directly From Alzheimer's Brains Impair Synaptic Plasticity And Memory” Aug. 2008, Nature Medicine 14(8):837-842.
[cited by applicant]
Shankar et al. “Natural Oligomers of the Alzheimer Amyloid-Beta Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway” Mar. 14, 2007, The J. Neuroscience 27(11)…
[cited by applicant]
Shin et al. “Zingerone as an Antioxidant Against Peroxynitrite” 2005, J. Agricultural and Food Chemistry 53:7617-7622.
[cited by applicant]
Shrestha et al. “Amyloid Beta Peptide Adversely Affects Spine No. and Motility in Hippocampal Neurons” Nov. 2006, Molecular and Cellular Neuroscience 33(3):274-282, DOI:10.1016/j.mcn.2006.07.011, XP024908115.
[cited by applicant]
Snyder et al. “Regulation of NMDA Receptor Trafficking By Amyloid-Beta” Aug. 2005, Nature Neuroscience 8(8):1051-1058.
[cited by applicant]
Song et al. “Memantine Protects Rat Cortical Cultured Neurons Against ß-Amyloid-Induced Toxicity by Attenuating Tau Phosphorylation” 2008, European J. of Neuroscience 28:1989-2002.
[cited by applicant]
Subbarayappa et al. “An Efficient Method for the Synthesis of 2,3-Dihydro-1H-Isoindoles” Apr. 2009, Indian J. Chemistry, DE 488:545-552, ISSN 0019-5103, XP055371729.
[cited by applicant]
Surh et al. “Enzymic Reduction of [6]-Gingerol, A Major Pungent Principle of Ginger, in the Cell-Free Preparation of Rat Liver” 1994, Life Sciences 54(19):321-326.
[cited by applicant]
Terry “Cell Death or Synaptic Loss in Alzheimer's Disease” Dec. 2000, J. Neuropathology & Experimental Neurology 59,(12):1118-1119.
[cited by applicant]
Ting et al. “Amyloid Precursor Protein Overexpression Depresses Excitatory Transmission through Both Presynaptic and Postsynaptic Mechanisms” Jan. 2, 2007, Proceedings of the National Academy of Sciences of the United S…
[cited by applicant]
Tomiyama et al. “A New Amyloid ß Variant Favoring Oligomerization in Alzheimer's-Type Dementia” Mar. 2008, Annals of Neurology 63(03):377-387.
[cited by applicant]
Tong et al. “ß-Amyloid Peptide At Sublethal Concentrations Downregulates Brain-Derived Neurotrophic Factor Functions in Cultured Cortical Neurons” Jul. 28, 2004, The J. Neuroscience 24(30):6799-6809.
[cited by applicant]